IL17A and Alzheimer disease: We reported a reduction in genes via miRNAs that control production of chemokines and cytokines and other inflammatory markers in the CSF of nilotinib-treated AD patients compared to placebo [6], in agreement with CSF reduction in IL-17a and pre-clinical data that DDR1 inhibition facilitates autophagy and reduces inflammation [27].